Swissmedic is step­ping up its com­mit­ment to patient safe­ty by launch­ing a new, tar­get­ed ini­tia­tive on post mar­ket sur­veil­lance. This cam­paign, recent­ly high­light­ed on LinkedIn, empha­sizes the impor­tance of con­tin­u­ous mon­i­tor­ing and eval­u­a­tion of prod­ucts even after they enter the market.

The ini­tia­tive aims to inten­si­fy over­sight, ensur­ing that any devi­a­tions from reg­u­la­to­ry stan­dards are quick­ly iden­ti­fied and addressed. Through enhanced inspec­tions and clos­er col­lab­o­ra­tion with man­u­fac­tur­ers, Swissmedic strives to detect poten­tial issues ear­ly, safe­guard­ing pub­lic health and strength­en­ing trust in reg­u­la­to­ry processes.

This strate­gic focus marks a pro­gres­sive move toward rig­or­ous post approval mon­i­tor­ing. By remain­ing vig­i­lant through­out a product’s life­cy­cle, Swissmedic reaf­firms its ded­i­ca­tion to main­tain­ing high safe­ty stan­dards and pro­mot­ing trans­paren­cy with­in the health­care market.

Man­u­fac­tur­ers are encour­aged to proac­tive­ly align with these enhanced mea­sures to ensure com­pli­ance with the lat­est safe­ty bench­marks. Remark­ably, Swissmedic con­firmed 20 non-con­for­mi­ties in 30 inves­ti­gat­ed products.

Source: Swissmedic 

Accom­pa­ny­ing this sub­ject we rec­om­mend the fol­low­ing con­tent on our website